Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Perspective Therapeutics (CATX)
NYSE MKT:CATX
RESEARCH TOOLSreports
Perspective Therapeutics (CATX) Stock Price & Analysis
1,036 Followers
CATX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.05 - $19.05
Previous Close$12.64
Volume215.16K
Average Volume (3M)894.19K
Market Cap
$873.22M
Enterprise Value$845.63M
Total Cash (Recent Filing)$9.24M
Total Debt (Recent Filing)$2.55M
Price to Earnings (P/E)―
Beta0.70
Next Earnings
Aug 09, 2024EPS Estimate
-$0.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.93
Shares Outstanding67,378,432
10 Day Avg. Volume959,807
30 Day Avg. Volume894,191
Standard Deviation0.46
R-Squared0.03
Alpha0.06
Financial Highlights & Ratios
Price to Book (P/B)21.70
Price to Sales (P/S)271.40
Price to Cash Flow (P/CF)-21.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue118.85
Enterprise Value/Gross Profit589.70
Enterprise Value/Ebitda-29.93
Forecast
1Y Price Target
$22.20Price Target Upside71.43% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Perspective Therapeutics News
Bulls Say, Bears Say
Bulls Say
Competitive PositionThe company is well positioned to establish itself as a leader in the rapidly advancing radiopharmaceutical field.
Financial PerformanceNuclear medicine represents an increasingly profitable segment for hospitals, which has the potential to drive continued commercial uptake of radiopharmaceutical products.
Market DemandTreatment centers dedicated to administering radiopharmaceuticals are coming online largely in response to demand for Pluvicto and in anticipation of additional product approvals.
Bears Say
Adverse EventsFour fatal adverse events were reported, including deaths due to progressive disease, carcinoid syndrome, and sepsis.
Clinical Trial DataInsufficient data from AlphaMedix's Phase II trial in RLT-naive NET patients could hinder accelerated approval.
Patient SafetyThe increased rate of severe lymphopenia in RLT-naive patients is alarming.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CATX FAQ
What was Perspective Therapeutics’s price range in the past 12 months?
Perspective Therapeutics lowest stock price was $2.05 and its highest was $19.05 in the past 12 months.
What is Perspective Therapeutics’s market cap?
Currently, no data Available
When is Perspective Therapeutics’s upcoming earnings report date?
Perspective Therapeutics’s upcoming earnings report date is Aug 09, 2024 which is in 18 days.
How were Perspective Therapeutics’s earnings last quarter?
Perspective Therapeutics released its earnings results on May 15, 2024. The company reported -$0.2 earnings per share for the quarter, beating the consensus estimate of -$0.28 by $0.08.
Is Perspective Therapeutics overvalued?
According to Wall Street analysts Perspective Therapeutics’s price is currently Undervalued.
Does Perspective Therapeutics pay dividends?
Perspective Therapeutics does not currently pay dividends.
What is Perspective Therapeutics’s EPS estimate?
Perspective Therapeutics’s EPS estimate is -$0.21.
How many shares outstanding does Perspective Therapeutics have?
Perspective Therapeutics has 67,430,000 shares outstanding.
What happened to Perspective Therapeutics’s price movement after its last earnings report?
Perspective Therapeutics reported an EPS of -$0.2 in its last earnings report, beating expectations of -$0.28. Following the earnings report the stock price went down -10.795%.
Which hedge fund is a major shareholder of Perspective Therapeutics?
Among the largest hedge funds holding Perspective Therapeutics’s share is Deerfield Management Company, LP. It holds Perspective Therapeutics’s shares valued at 34M.
---
Perspective Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$22.20 (71.43% Upside)
$22.20 (71.43% Upside)
Hedge Fund Trend
Increased
By 2.1M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $385.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.3%
Last 30 Days ▲ 9.0%
Last 30 Days ▲ 9.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
105.86%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
118.02%
Trailing 12-Months
Company Description
Perspective Therapeutics
IsoRay, Inc. is a medical technology company, which engages in the development, manufacture, and sale of isotope-based medical products and devices. The company focuses on the treatment of cancer and other malignant diseases. Its core product is Cesium-131, a radioisotope for the treatment of malignant tumors. The company was founded by Lance A. Bray in 1983 and is headquartered in Richland, WA.
---
CATX Stock 12 Month Forecast
Average Price Target
$22.20
▲(71.43% Upside)
Technical Analysis
Best Analysts Covering CATX
1 Year
1 Year Success Rate
5/6 ratings generated profit
1 Year Average Return
+141.08%
reiterated a buy rating 7 days ago
Copying Justin Walsh's trades and holding each position for 1 Year would result in 83.33% of your transactions generating a profit, with an average return of +141.08% per trade.
---